In vivo molecular imaging enables non-invasive visualization of biological processes within living subjects, and holds great promise for diagnosis and monitoring of disease. The ability to create new agents that bind to molecular targets and deliver imaging probes to desired locations in the body is critically important to further advance this field. To address this need, phage display, an established technology for the discovery and development of novel binding agents, is increasingly becoming a key component of many molecular imaging research programs. This review discusses the expanding role played by phage display in the field of molecular imaging with a focus on in vivo applications. Furthermore, new methodological advances in phage display that can be directly applied to the discovery and development of molecular imaging agents are described. Various phage library selection strategies are summarized and compared, including selections against purified target, intact cells, and ex vivo tissue, plus in vivo homing strategies. An outline of the process for converting polypeptides obtained from phage display library selections into successful in vivo imaging agents is provided, including strategies to optimize in vivo performance. Additionally, the use To whom correspondence may be addressed (cochran1@stanford.edu) Abbreviations: scFv, single chain variable fragment; Fab, fragment antigen binding; ELISA, Enzyme-Linked Immunosorbent Assay; NEB, New England Biolabs; PET, positron emission tomography; SPECT, single photon emission computed tomography; NIR, near infrared; PEG, polyethylene glycol; SPARC, secreted protein acidic and rich in cysteine; VCAM-1, vascular cell adhesion molecule; MRI, magnetic resonance imaging; DOTA, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; IC 50 , half maximal inhibitory concentration; CT, computed tomography; K D , equilibrium dissociation constant; EGFR, epidermal growth factor receptor; EGFR-ECD, EGFR extracellular domain; Aβ 42 , amyloid-beta; MMP, matrix metalloprotease; uPAR, urokinase-type plasminogen activator receptor; VEGF, vascular endothelial growth factor; IL-11, Interleukin-11; IL-11αR, Interleukin-11 α-receptor.
58F.V. CoChran and J.r. CoChran of phage particles as imaging agents is also described. In the latter part of the review, a survey of phage-derived in vivo imaging agents is presented, and important recent examples are highlighted. Other imaging applications are also discussed, such as the development of peptide tags for site-specific protein labeling and the use of phage as delivery agents for reporter genes. The review concludes with a discussion of how phage display technology will continue to impact both basic science and clinical applications in the field of molecular imaging.